330 related articles for article (PubMed ID: 17878749)
1. The soluble epoxide hydrolase as a pharmaceutical target for hypertension.
Chiamvimonvat N; Ho CM; Tsai HJ; Hammock BD
J Cardiovasc Pharmacol; 2007 Sep; 50(3):225-37. PubMed ID: 17878749
[TBL] [Abstract][Full Text] [Related]
2. Epoxyeicosanoids in hypertension.
Imig JD
Physiol Res; 2019 Oct; 68(5):695-704. PubMed ID: 31475560
[TBL] [Abstract][Full Text] [Related]
3. Soluble epoxide hydrolase inhibitors and cardiovascular diseases.
Wang ZH; Davis BB; Jiang DQ; Zhao TT; Xu DY
Curr Vasc Pharmacol; 2013 Jan; 11(1):105-11. PubMed ID: 22303912
[TBL] [Abstract][Full Text] [Related]
4. Soluble epoxide hydrolase: a novel target for the treatment of hypertension.
Fang X
Recent Pat Cardiovasc Drug Discov; 2006 Jan; 1(1):67-72. PubMed ID: 18221075
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain.
Inceoglu B; Jinks SL; Schmelzer KR; Waite T; Kim IH; Hammock BD
Life Sci; 2006 Nov; 79(24):2311-9. PubMed ID: 16962614
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors.
Imig JD
Cardiovasc Drug Rev; 2006; 24(2):169-88. PubMed ID: 16961727
[TBL] [Abstract][Full Text] [Related]
7. Soluble epoxide hydrolase: A potential target for metabolic diseases.
He J; Wang C; Zhu Y; Ai D
J Diabetes; 2016 May; 8(3):305-13. PubMed ID: 26621325
[TBL] [Abstract][Full Text] [Related]
8. ANTIHYPERTENSIVE AND CARDIOPROTECTIVE EFFECTS OF EPOXYEICOSATRIENOIC ACID ANALOGS AND SOLUBLE EPOXIDE HYDROLASE INHIBITORS (REVIEW).
Papiashvili N; Gongadze N; Bakuridze A; Bakuridze K
Georgian Med News; 2021 Mar; (312):125-132. PubMed ID: 33964840
[TBL] [Abstract][Full Text] [Related]
9. Soluble epoxide hydrolase inhibitors: an overview and patent review from the last decade.
Iyer MR; Kundu B; Wood CM
Expert Opin Ther Pat; 2022 Jun; 32(6):629-647. PubMed ID: 35410559
[TBL] [Abstract][Full Text] [Related]
10. Epoxyeicosatrienoic acid pathway in human health and diseases.
Bellien J; Joannides R
J Cardiovasc Pharmacol; 2013 Mar; 61(3):188-96. PubMed ID: 23011468
[TBL] [Abstract][Full Text] [Related]
11. Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension.
Jung O; Brandes RP; Kim IH; Schweda F; Schmidt R; Hammock BD; Busse R; Fleming I
Hypertension; 2005 Apr; 45(4):759-65. PubMed ID: 15699457
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological inhibition of the soluble epoxide hydrolase-from mouse to man.
Revermann M
Curr Opin Pharmacol; 2010 Apr; 10(2):173-8. PubMed ID: 20079692
[TBL] [Abstract][Full Text] [Related]
13. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases.
Imig JD; Hammock BD
Nat Rev Drug Discov; 2009 Oct; 8(10):794-805. PubMed ID: 19794443
[TBL] [Abstract][Full Text] [Related]
14. Soluble epoxide hydrolase inhibitors and heart failure.
Qiu H; Li N; Liu JY; Harris TR; Hammock BD; Chiamvimonvat N
Cardiovasc Ther; 2011 Apr; 29(2):99-111. PubMed ID: 20433684
[TBL] [Abstract][Full Text] [Related]
15. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors.
Xu D; Li N; He Y; Timofeyev V; Lu L; Tsai HJ; Kim IH; Tuteja D; Mateo RK; Singapuri A; Davis BB; Low R; Hammock BD; Chiamvimonvat N
Proc Natl Acad Sci U S A; 2006 Dec; 103(49):18733-8. PubMed ID: 17130447
[TBL] [Abstract][Full Text] [Related]
16. Soluble epoxide hydrolase: a promising therapeutic target for cardiovascular diseases.
Ni GH; Chen JF; Chen XP; Yang TL
Pharmazie; 2011 Mar; 66(3):153-7. PubMed ID: 21553642
[TBL] [Abstract][Full Text] [Related]
17. Oral treatment of rodents with soluble epoxide hydrolase inhibitor 1-(1-propanoylpiperidin-4-yl)-3-[4-(trifluoromethoxy)phenyl]urea (TPPU): Resulting drug levels and modulation of oxylipin pattern.
Ostermann AI; Herbers J; Willenberg I; Chen R; Hwang SH; Greite R; Morisseau C; Gueler F; Hammock BD; Schebb NH
Prostaglandins Other Lipid Mediat; 2015 Sep; 121(Pt A):131-7. PubMed ID: 26117215
[TBL] [Abstract][Full Text] [Related]
18. Targeting epoxides for organ damage in hypertension.
Imig JD
J Cardiovasc Pharmacol; 2010 Oct; 56(4):329-35. PubMed ID: 20531214
[TBL] [Abstract][Full Text] [Related]
19. Measurement of soluble epoxide hydrolase (sEH) activity.
Morisseau C; Hammock BD
Curr Protoc Toxicol; 2007; Chapter 4():Unit 4.23. PubMed ID: 23045145
[TBL] [Abstract][Full Text] [Related]
20. Anti-inflammatory effects of ω-3 polyunsaturated fatty acids and soluble epoxide hydrolase inhibitors in angiotensin-II-dependent hypertension.
Ulu A; Harris TR; Morisseau C; Miyabe C; Inoue H; Schuster G; Dong H; Iosif AM; Liu JY; Weiss RH; Chiamvimonvat N; Imig JD; Hammock BD
J Cardiovasc Pharmacol; 2013 Sep; 62(3):285-97. PubMed ID: 23676336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
